Orexigen Therapeutics, Inc. (NASDAQ:OREX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.


Player Avatar jed71 (88.57) Submitted: 6/28/2012 11:11:08 AM : Underperform Start Price: $5.53 OREX Score: +29.99

Obesity drug still not approved yet. Run up based on expectations and approval received by a different company, Arena Pharma, for a similar obesity drug. It will not hold the run up, because, well, OREX never holds these run ups.

Featured Broker Partners